Report Overview
The Obesity-Related Cancer market is projected to grow at a CAGR of 11.4% over the forecast period, increasing from USD 114.2 billion in 2026 to USD 195.9 billion by 2031.
The market exists because obesity is amplifying the incidence of several cancers through endocrine and inflammatory mechanisms. Demand is rising for therapies that can address tumor progression influenced by insulin resistance and adipokine signaling. Treatment dependency is increasing on immune checkpoint inhibitors and kinase inhibitors as these mechanisms directly interact with obesity-driven pathways. Regulatory frameworks are supporting accelerated approvals in oncology, which is enabling faster access to therapies across indications linked to obesity. Clinical practice is incorporating biomarker driven stratification, which is narrowing treatment selection toward patients with specific molecular profiles. Strategic importance is increasing as healthcare systems are prioritizing early intervention and targeted therapies to manage rising cancer burden associated with obesity.
Market Dynamics
Market Drivers
Rising Obesity-Driven Cancer Incidence: Cancer incidence linked to obesity is expanding due to metabolic dysregulation. Patient populations are increasing as obesity prevalence is rising across both developed and emerging markets. Screening systems remain limited, which delays diagnosis and increases reliance on advanced-stage treatments. Oncology providers are adopting systemic therapies more aggressively to manage late-stage presentations. The market is expanding as treatment demand is rising in parallel with obesity-driven cancer burden.
Expansion of Immuno-Oncology Therapies: Immunotherapy forms a core treatment backbone in modern oncology. Clinical adoption is accelerating as immune checkpoint inhibitors are demonstrating durable responses across multiple cancers. Treatment costs remain high, which constrains accessibility in lower-income settings. Pharmaceutical companies are expanding indications and combination regimens to enhance response rates. The market is evolving toward immunotherapy dominance as demand is shifting away from traditional chemotherapy.
Growth in Targeted Therapy Utilization: Targeted therapies define precision oncology approaches. Adoption is increasing as molecular diagnostics are identifying actionable mutations in obesity-related cancers. Drug resistance remains a constraint, which limits long-term efficacy. Companies are developing next-generation inhibitors to overcome resistance pathways. The market is stabilizing around targeted approaches as treatment personalization is improving outcomes.
Increasing Role of Hormonal Therapies: Hormonal therapies remain essential in hormone-driven cancers. Demand is increasing as obesity is elevating estrogen-related cancer risk in postmenopausal populations. Treatment adherence challenges persist, which impacts long-term outcomes. Healthcare systems are promoting long-duration therapy regimens to maintain disease control. The market is sustaining steady demand as hormonal pathways remain central in obesity-linked cancers.
Market Restraints
High treatment costs reduce accessibility, which limits adoption in cost-sensitive regions
Variability in therapeutic response in obese patients complicates treatment standardization
Limited early detection infrastructure delays diagnosis, increasing treatment complexity
Market Opportunities
Integration of Metabolic and Oncology Therapeutics: Metabolic dysfunction is directly influencing cancer progression. Research is expanding as therapies targeting metabolic pathways are being evaluated alongside oncology drugs. Clinical validation remains limited, which slows widespread adoption. Companies are conducting trials integrating metabolic modulators with cancer therapies. The market is opening new therapeutic avenues as metabolic-oncology integration is gaining traction.
Expansion of Biomarker-Driven Therapies: Biomarkers define treatment eligibility and response prediction. Testing adoption is increasing as precision medicine frameworks are expanding globally. Infrastructure limitations constrain access in developing regions. Diagnostic companies are scaling testing capabilities to support oncology treatment decisions. The market is becoming more selective as biomarker-driven therapy is improving clinical outcomes.
Combination Therapy Development: Combination regimens address resistance mechanisms in cancer treatment. Clinical trials are increasing as multi-drug approaches are being evaluated across obesity-related cancers. Toxicity management remains a constraint in complex regimens. Pharmaceutical companies are optimizing dosing strategies to balance efficacy and safety. The market is shifting toward combination approaches as treatment resistance is being actively addressed.
Supply Chain Analysis
The oncology supply chain depends on complex biologics manufacturing and cold-chain logistics. Demand is increasing as biologic therapies are expanding across indications. Manufacturing capacity constraints persist, which limits rapid scalability of biologics. Companies are investing in production facilities to increase output and reduce supply bottlenecks. Distribution networks are evolving to ensure timely delivery of temperature-sensitive therapies. The supply chain is stabilizing as infrastructure investment is supporting growing oncology demand.
Government Regulations
Region | Regulatory Authority | Key Role |
United States | FDA | Drug approval, accelerated oncology pathways |
Europe | EMA | Centralized drug authorization |
Japan | PMDA | Clinical evaluation and approvals |
India | CDSCO | Drug regulation and approval |
China | NMPA | Market authorization and compliance |
Market Segmentation
By Therapy Type
Therapy type segmentation defines treatment selection across oncology pathways. Immunotherapy demand is increasing as immune checkpoint inhibitors are becoming standard care in multiple cancers. Chemotherapy remains relevant, but its usage is declining due to toxicity concerns. Targeted therapy adoption is expanding as molecular profiling is improving treatment precision. Hormonal therapy continues to serve hormone-driven cancers, particularly in obese populations with elevated estrogen levels. The segment is evolving as immunotherapy and targeted therapies are dominating treatment paradigms.
By Drug Class
Drug class segmentation reflects mechanistic diversity in cancer treatment. PD-1/PD-L1 inhibitors are gaining dominance as they modulate immune response effectively. CDK4/6 inhibitors are expanding in breast cancer due to improved progression-free survival. VEGF inhibitors continue to address angiogenesis but face competition from newer agents. PARP inhibitors are targeting DNA repair pathways in specific populations. The segment is consolidating as biologics and targeted agents are driving therapeutic innovation.
By Indication
Indication-based segmentation captures disease-specific demand patterns. Breast cancer dominates due to strong linkage with obesity and hormonal imbalance. Colorectal and endometrial cancers are increasing as metabolic factors influence disease progression. Hepatocellular carcinoma demand is rising due to obesity-driven liver disease. Treatment complexity varies across indications, which affects therapy selection. The segment is expanding as multiple cancer types are being influenced by obesity prevalence.
Regional Analysis
North America Market Analysis
The North American market is defined by high obesity prevalence and advanced oncology infrastructure. Demand is increasing as cancer incidence linked to obesity is rising significantly. Treatment accessibility remains relatively strong, although high therapy costs create affordability challenges. Pharmaceutical companies are expanding immunotherapy adoption through clinical evidence and reimbursement support. Healthcare systems are prioritizing early diagnosis and targeted treatment strategies. The market remains dominant as innovation and infrastructure are supporting sustained demand growth.
Europe Market Analysis
The European market operates under centralized regulatory frameworks and strong healthcare systems. Demand is increasing as aging populations and obesity prevalence are driving cancer incidence. Cost containment policies constrain pricing flexibility for advanced therapies. Companies are adapting pricing strategies to align with reimbursement frameworks. Clinical adoption of targeted therapies is expanding across major markets. The market remains stable as regulatory alignment supports consistent therapy access.
Asia Pacific Market Analysis
The Asia Pacific market is experiencing rapid growth due to rising obesity rates and expanding healthcare infrastructure. Demand is increasing as urbanization is contributing to lifestyle-related diseases. Access disparities persist across countries, which limits uniform treatment adoption. Governments are investing in oncology infrastructure to improve access. Pharmaceutical companies are expanding presence through partnerships and localized production. The market is accelerating as healthcare investment is supporting oncology demand expansion.
Rest of the World
The Rest of the World market includes emerging economies with growing cancer burden. Demand is increasing as obesity rates are rising in urban populations. Limited healthcare infrastructure constrains treatment availability. Governments are improving healthcare access through policy reforms and investment. Pharmaceutical companies are targeting these markets with cost-effective therapies. The market is developing as access improvements are enabling gradual adoption of oncology treatments.
Regulatory Landscape
Regulatory frameworks define approval timelines and market entry strategies for oncology therapies. Agencies such as FDA and EMA are accelerating approvals through priority review pathways for cancer drugs. Approval processes remain stringent, which ensures safety and efficacy standards. Regulatory harmonization is improving across regions, which simplifies global drug development. Companies are aligning clinical strategies with regulatory requirements to expedite approvals. The regulatory landscape supports innovation while maintaining strict evaluation standards.
Clinical trial regulations are evolving to incorporate adaptive trial designs. Patient recruitment is increasing as oncology trials are expanding across regions. Ethical and compliance requirements remain stringent, which increases trial complexity. Regulatory bodies are enabling faster trial approvals to support innovation. The system is evolving as clinical research frameworks are adapting to rapid oncology advancements.
Pipeline Analysis
The oncology pipeline reflects increasing focus on immunotherapy and targeted therapies. Clinical trials are expanding as companies are developing next-generation inhibitors and combination regimens. Early-stage trials are exploring metabolic pathway modulation in cancer treatment. Success rates remain uncertain, which creates risk in drug development. Companies are prioritizing late-stage trials to accelerate commercialization. The pipeline is strengthening as innovation is focusing on precision oncology.
Combination therapy trials are increasing as resistance mechanisms limit monotherapy effectiveness. Clinical outcomes are improving as multi-drug approaches are being validated. Safety concerns remain a constraint in combination regimens. Pharmaceutical companies are optimizing dosing strategies to balance efficacy and toxicity. The pipeline is evolving toward combination therapies as treatment resistance is being addressed.
Competitive Landscape
Merck & Co., Inc.
The company leads in immuno-oncology through pembrolizumab. Demand is increasing as the drug is expanding across multiple cancer indications. Competition is intensifying from other checkpoint inhibitors. The company is expanding clinical trials to sustain market leadership. The company maintains dominance as immunotherapy adoption continues to rise.
Bristol-Myers Squibb
The company competes strongly with nivolumab in immunotherapy. Demand is increasing as combination regimens are being adopted in oncology treatment. Pricing pressures constrain market expansion. The company is focusing on combination strategies to enhance efficacy. The company sustains competitive positioning through diversified oncology portfolio.
F. Hoffmann-La Roche Ltd
The company operates across both targeted therapy and immunotherapy segments. Demand is increasing as bevacizumab and atezolizumab are widely used in oncology. Biosimilar competition affects revenue growth. The company is investing in pipeline innovation to maintain relevance. The company remains a key player due to diversified therapeutic offerings.
Eisai Co., Ltd.
The company focuses on targeted therapies such as lenvatinib. Demand is increasing as liver and endometrial cancer cases rise. Competition from alternative therapies limits growth. The company is expanding combination therapies with immuno-oncology agents. The company strengthens its position through strategic collaborations.
Bayer AG
The company offers multikinase inhibitors such as sorafenib. Demand is stable as hepatocellular carcinoma cases persist. Newer therapies reduce reliance on older drugs. The company is investing in next-generation oncology treatments. The company maintains relevance through established oncology presence.
Pfizer Inc.
The company focuses on CDK4/6 inhibitors such as palbociclib. Demand is increasing as breast cancer incidence rises. Competitive pressure exists from similar drugs. The company is expanding indications to sustain growth. The company remains competitive through strong clinical data.
Novartis AG
The company competes with ribociclib in breast cancer treatment. Demand is increasing as targeted therapy adoption grows. Pricing pressures affect market penetration. The company is strengthening clinical evidence to differentiate products. The company sustains growth through innovation.
Eli Lilly and Company
The company offers abemaciclib for breast cancer treatment. Demand is increasing as combination therapies are being adopted. Market competition intensifies within CDK4/6 inhibitors. The company is expanding clinical trials for broader indications. The company maintains competitive strength through targeted therapy expertise.
Key Developments
February 2026: Can-Fite BioPharma Ltd., a clinical-stage biotechnology company advancing a pipeline of proprietary small molecule drugs addressing oncological and inflammatory diseases, announced the publication of a peer-reviewed study in the International Journal of Obesity demonstrating the anti-obesity effect of namodenoson, the Company’s lead drug candidate.
December 2025: Boehringer Ingelheim announced the advancement of BI 3034701, its long?acting potential first-in-class triple?agonist peptide, in development for the treatment of obesity. This milestone reflects the company’s strategy to address the global burden of obesity and its interconnected cardiovascular, renal, metabolic (CRM) complications.
November 2025: Eli Lilly and Company announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs.
Strategic Insights and Future Market Outlook
The market is transitioning toward integrated treatment approaches that combine metabolic and oncologic pathways. Demand is increasing as obesity-related cancers are becoming a larger share of global cancer burden. Treatment strategies are evolving as precision medicine is enabling more targeted interventions. Healthcare systems are adapting to manage rising costs and complexity of oncology care. The market is expected to expand as innovation continues across immunotherapy and targeted therapies.
The future outlook is shaped by increasing focus on biomarker-driven therapies and combination regimens. Demand is shifting as healthcare providers prioritize personalized treatment strategies. Regulatory support continues to accelerate drug approvals, which enhances market entry for new therapies. Pharmaceutical companies are investing in research to address unmet needs in obesity-linked cancers. The market is evolving toward more effective and personalized oncology care.
The obesity-related cancer market is becoming structurally dependent on precision oncology, where treatment effectiveness is increasingly tied to metabolic and molecular profiling, establishing a long-term shift toward highly specialized therapeutic strategies.
Obesity-Related Cancer Market Scope:
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 114.2 billion |
| Total Market Size in 2031 | USD 195.9 billion |
| Forecast Unit | USD Billion |
| Growth Rate | 11.4% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Therapy Type, Drug Class, Indication, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|
Market Segmentation
By Geography
Key Countries Analysis
Regulatory & Policy Landscape
Table of Contents
1. EXECUTIVE SUMMARY
1.1 Market Overview
1.2 Scope and Definition of Obesity-Related Cancer Market
1.3 Key Insights
1.4 Approved Therapeutics Snapshot (Obesity-Associated Indications)
1.5 Market Outlook
2. DISEASE & EPIDEMIOLOGY ANALYSIS
2.1 Overview of Obesity-Related Cancers
2.1.1 Biological Mechanisms Linking Obesity and Cancer
2.1.2 Role of Adiposity, Insulin Resistance, and Inflammation
2.2 Major Obesity-Associated Cancer Types
2.2.1 Breast Cancer (HR+/HER2?, Postmenopausal)
2.2.2 Colorectal Cancer
2.2.3 Endometrial Cancer
2.2.4 Hepatocellular Carcinoma
2.2.5 Esophageal Adenocarcinoma
2.2.6 Pancreatic Cancer
2.2.7 Renal Cell Carcinoma
2.3 Epidemiology by Indication
2.3.1 Global Incidence and Prevalence
2.3.2 Obesity-Attributable Fraction by Cancer Type
2.3.3 Mortality Trends
2.4 Subtype-Level Epidemiology
2.4.1 Hormone Receptor Status (Breast, Endometrial)
2.4.2 Molecular Subtypes (MSI-H/dMMR in Colorectal/Endometrial)
2.5 Patient Demographics
2.5.1 BMI Stratification
2.5.2 Age and Gender Distribution
2.5.3 Comorbidities (Diabetes, NAFLD/NASH)
3. OBESITY-RELATED CANCER MARKET DYNAMICS
3.1 Market Drivers
3.1.1 Increasing Global Obesity Burden
3.1.2 Rising Incidence of Obesity-Linked Malignancies
3.1.3 Expansion of Immuno-Oncology and Targeted Therapies
3.2 Market Restraints
3.2.1 High Treatment Costs
3.2.2 Variability in Treatment Outcomes in Obese Populations
3.3 Market Opportunities
3.3.1 Integration of Metabolic and Oncology Therapeutics
3.3.2 Biomarker-Driven Precision Medicine
3.4 Market Challenges
3.4.1 Complex Pathophysiology
3.4.2 Limited Preventive Strategies
4. COMMERCIAL & MARKET ACCESS
4.1 Pricing Analysis of Key Oncology Therapies
4.2 Reimbursement Landscape
4.2.1 Public and Private Payers
4.2.2 HTA and Value-Based Pricing
4.3 Market Access Barriers
4.4 Patient Support and Access Programs
5. INNOVATION & PIPELINE LANDSCAPE
5.1 Pipeline Overview
5.2 Pipeline by Phase
5.2.1 Phase I
5.2.2 Phase II
5.2.3 Phase III
5.3 Mechanism of Action (MoA)
5.3.1 PD-1/PD-L1 Inhibitors
5.3.2 CTLA-4 Inhibitors
5.3.3 VEGF/VEGFR Inhibitors
5.3.4 CDK4/6 Inhibitors
5.3.5 PARP Inhibitors
5.3.6 PI3K/AKT/mTOR Pathway Inhibitors
5.3.7 Hormonal Modulators
5.4 Modality Analysis
5.4.1 Small Molecules
5.4.2 Monoclonal Antibodies
5.4.3 Antibody-Drug Conjugates
5.4.4 Cell Therapies
5.5 Clinical Trial Landscape (ClinicalTrials.gov / EU CTR Verified)
6. TREATMENT LANDSCAPE
6.1 Standard of Care by Indication
6.1.1 Breast Cancer
6.1.2 Colorectal Cancer
6.1.3 Endometrial Cancer
6.1.4 Hepatocellular Carcinoma
6.2 Approved Drug Classes and Key Therapies
6.2.1 Immune Checkpoint Inhibitors
6.2.1.1 Pembrolizumab (Keytruda)
6.2.1.2 Nivolumab (Opdivo)
6.2.1.3 Atezolizumab (Tecentriq)
6.2.2 Targeted Therapies
6.2.2.1 Bevacizumab (Avastin)
6.2.2.2 Lenvatinib (Lenvima)
6.2.2.3 Sorafenib (Nexavar)
6.2.3 CDK4/6 Inhibitors
6.2.3.1 Palbociclib (Ibrance)
6.2.3.2 Ribociclib (Kisqali)
6.2.3.3 Abemaciclib (Verzenio)
6.2.4 PARP Inhibitors
6.2.4.1 Olaparib (Lynparza)
6.2.5 Hormonal Therapies
6.2.5.1 Tamoxifen
6.2.5.2 Letrozole
6.2.5.3 Anastrozole
6.3 Combination Therapy Strategies
6.4 Impact of Obesity on Pharmacokinetics and Outcomes
7. OBESITY-RELATED CANCER MARKET SIZE & FORECAST
7.1 Historical Market Size Analysis
7.2 Forecast (2026–2035)
7.3 CAGR Analysis
7.4 Market Share by Therapy Type
8. MARKET SEGMENTATION
8.1 By Therapy Type
8.1.1 Chemotherapy
8.1.2 Targeted Therapy
8.1.3 Immunotherapy
8.1.4 Hormonal Therapy
8.2 By Drug Class
8.2.1 PD-1/PD-L1 Inhibitors
8.2.2 VEGF Inhibitors
8.2.3 CDK4/6 Inhibitors
8.2.4 PARP Inhibitors
8.2.5 Aromatase Inhibitors
8.3 By Indication
8.3.1 Breast Cancer
8.3.2 Colorectal Cancer
8.3.3 Endometrial Cancer
8.3.4 Liver Cancer
8.3.5 Pancreatic Cancer
8.4 By Route of Administration
8.4.1 Oral
8.4.2 Intravenous
8.4.3 Subcutaneous
8.5 By End User
8.5.1 Hospitals
8.5.2 Cancer Specialty Centers
8.5.3 Ambulatory Care Centers
8.6 By Distribution Channel
8.6.1 Hospital Pharmacies
8.6.2 Retail Pharmacies
8.6.3 Online Pharmacies
9. GEOGRAPHICAL ANALYSIS (REGIONAL LEVEL)
9.1 North America
9.1.1 Market Size & Growth
9.1.2 Demand Drivers
9.1.3 Regulatory Overview
9.1.4 Competitive Intensity
9.2 Europe
9.2.1 Market Size & Growth
9.2.2 Demand Drivers
9.2.3 Regulatory Overview
9.2.4 Competitive Intensity
9.3 Asia-Pacific
9.3.1 Market Size & Growth
9.3.2 Demand Drivers
9.3.3 Regulatory Overview
9.3.4 Competitive Intensity
9.4 Latin America
9.4.1 Market Size & Growth
9.4.2 Demand Drivers
9.4.3 Regulatory Overview
9.4.4 Competitive Intensity
9.5 Middle East & Africa
9.5.1 Market Size & Growth
9.5.2 Demand Drivers
9.5.3 Regulatory Overview
9.5.4 Competitive Intensity
10. KEY COUNTRIES ANALYSIS
10.1 United States
10.1.1 Market Size
10.1.2 Epidemiology
10.1.3 Regulatory Framework (FDA)
10.1.4 Reimbursement
10.1.5 Key Companies and Approved Products
10.2 Canada
10.2.1 Market Size
10.2.2 Epidemiology
10.2.3 Regulatory Framework
10.2.4 Reimbursement
10.2.5 Key Companies and Approved Products
10.3 Germany
10.3.1 Market Size
10.3.2 Epidemiology
10.3.3 Regulatory Framework
10.3.4 Reimbursement
10.3.5 Key Companies and Approved Products
10.4 United Kingdom
10.4.1 Market Size
10.4.2 Epidemiology
10.4.3 Regulatory Framework
10.4.4 Reimbursement
10.4.5 Key Companies and Approved Products
10.5 France
10.5.1 Market Size
10.5.2 Epidemiology
10.5.3 Regulatory Framework
10.5.4 Reimbursement
10.5.5 Key Companies and Approved Products
10.6 Italy
10.6.1 Market Size
10.6.2 Epidemiology
10.6.3 Regulatory Framework
10.6.4 Reimbursement
10.6.5 Key Companies and Approved Products
10.7 Spain
10.7.1 Market Size
10.7.2 Epidemiology
10.7.3 Regulatory Framework
10.7.4 Reimbursement
10.7.5 Key Companies and Approved Products
10.8 China
10.8.1 Market Size
10.8.2 Epidemiology
10.8.3 Regulatory Framework (NMPA)
10.8.4 Reimbursement
10.8.5 Key Companies and Approved Products
10.9 Japan
10.9.1 Market Size
10.9.2 Epidemiology
10.9.3 Regulatory Framework (PMDA)
10.9.4 Reimbursement
10.9.5 Key Companies and Approved Products
10.10 India
10.10.1 Market Size
10.10.2 Epidemiology
10.10.3 Regulatory Framework (CDSCO)
10.10.4 Reimbursement
10.10.5 Key Companies and Approved Products
10.11 South Korea
10.11.1 Market Size
10.11.2 Epidemiology
10.11.3 Regulatory Framework
10.11.4 Reimbursement
10.11.5 Key Companies and Approved Products
10.12 Australia
10.12.1 Market Size
10.12.2 Epidemiology
10.12.3 Regulatory Framework
10.12.4 Reimbursement
10.12.5 Key Companies and Approved Products
10.13 Brazil
10.13.1 Market Size
10.13.2 Epidemiology
10.13.3 Regulatory Framework
10.13.4 Reimbursement
10.13.5 Key Companies and Approved Products
10.14 Mexico
10.14.1 Market Size
10.14.2 Epidemiology
10.14.3 Regulatory Framework
10.14.4 Reimbursement
10.14.5 Key Companies and Approved Products
10.15 Saudi Arabia
10.15.1 Market Size
10.15.2 Epidemiology
10.15.3 Regulatory Framework
10.15.4 Reimbursement
10.15.5 Key Companies and Approved Products
10.16 South Africa
10.16.1 Market Size
10.16.2 Epidemiology
10.16.3 Regulatory Framework
10.16.4 Reimbursement
10.16.5 Key Companies and Approved Products
11. REGULATORY & POLICY LANDSCAPE
11.1 United States (FDA)
11.2 Europe (EMA / MDR)
11.3 Japan (PMDA)
11.4 India (CDSCO)
11.5 China (NMPA)
11.6 Oncology-Specific Regulatory Pathways and Accelerated Approvals
12. COMPETITIVE LANDSCAPE
12.1 Market Share Analysis
12.2 Strategic Developments
12.2.1 Mergers and Acquisitions
12.2.2 Collaborations and Partnerships
12.2.3 Licensing Agreements
12.3 Competitive Positioning
13. COMPANY PROFILES
13.1 Merck & Co., Inc.
13.1.1 Approved Products
13.1.1.1 Pembrolizumab (Keytruda)
13.1.1.2 Key Indications: MSI-H/dMMR colorectal cancer, endometrial cancer, triple-negative breast cancer
13.1.2 Pipeline (Phase I/II/III – Verified Clinical Trials)
13.2 Bristol-Myers Squibb
13.2.1 Approved Products
13.2.1.1 Nivolumab (Opdivo)
13.2.1.2 Key Indications: Hepatocellular carcinoma, colorectal cancer (MSI-H)
13.2.2 Pipeline (Phase I/II/III – Verified Clinical Trials)
13.3 F. Hoffmann-La Roche Ltd
13.3.1 Approved Products
13.3.1.1 Bevacizumab (Avastin)
13.3.1.2 Atezolizumab (Tecentriq)
13.3.1.3 Key Indications: Colorectal cancer, hepatocellular carcinoma, breast cancer
13.3.2 Pipeline (Phase I/II/III – Verified Clinical Trials)
13.4 Eisai Co., Ltd.
13.4.1 Approved Products
13.4.1.1 Lenvatinib (Lenvima)
13.4.1.2 Key Indications: Hepatocellular carcinoma, endometrial cancer
13.4.2 Pipeline (Phase I/II/III – Verified Clinical Trials)
13.5 Bayer AG
13.5.1 Approved Products
13.5.1.1 Sorafenib (Nexavar)
13.5.1.2 Key Indications: Hepatocellular carcinoma, renal cell carcinoma
13.5.2 Pipeline (Phase I/II/III – Verified Clinical Trials)
13.6 Pfizer Inc.
13.6.1 Approved Products
13.6.1.1 Palbociclib (Ibrance)
13.6.1.2 Key Indications: HR-positive breast cancer
13.6.2 Pipeline (Phase I/II/III – Verified Clinical Trials)
13.7 Novartis AG
13.7.1 Approved Products
13.7.1.1 Ribociclib (Kisqali)
13.7.1.2 Key Indications: HR-positive breast cancer
13.7.2 Pipeline (Phase I/II/III – Verified Clinical Trials)
13.8 Eli Lilly and Company
13.8.1 Approved Products
13.8.1.1 Abemaciclib (Verzenio)
13.8.1.2 Key Indications: HR-positive breast cancer
13.8.2 Pipeline (Phase I/II/III – Verified Clinical Trials)
13.9 AstraZeneca PLC
13.9.1 Approved Products
13.9.1.1 Olaparib (Lynparza)
13.9.1.2 Key Indications: Breast cancer (BRCA-mutated)
13.9.2 Pipeline (Phase I/II/III – Verified Clinical Trials)
13.10 Sanofi
13.10.1 Approved Products
13.10.1.1 Docetaxel (Taxotere)
13.10.1.2 Key Indications: Breast cancer and other solid tumors
13.10.2 Pipeline (Phase I/II/III – Verified Clinical Trials)
14. FUTURE OUTLOOK
14.1 Evolution of Metabolic-Oncology Therapeutics
14.2 Advancements in Combination Regimens
14.3 Expansion of Biomarker-Driven Therapies
14.4 Long-Term Market Growth Opportunities
15. METHODOLOGY
15.1 Research Methodology Overview
15.2 Data Sources (Primary and Secondary)
15.3 Forecasting Techniques
15.4 Assumptions and Limitations
Request Customization
Tell us your specific requirements and we will customize this report for you.
Download Free Sample
Get a sample copy of this report with charts, TOC, and methodology.
Speak to Analyst
Ask our analysts any questions you have about this market research report.
Obesity-Related Cancer Market Report
Trusted by the world's leading organizations
